712515
O-(3-Carboxypropyl)-O′-[2-(3-mercaptopropionylamino)ethyl]-polyethylene glycol
Mw 3000
Sinónimos:
Polyethylene glycol, α-Mercapto-ω-carboxy-PEG
About This Item
Productos recomendados
![O-(3-Carboxypropyl)-O′-[2-(3-mercaptopropionylamino)ethyl]-polyethylene glycol Mw 5000](/deepweb/assets/sigmaaldrich/product/structures/271/277/d02536f0-83d7-4416-9cea-f6213e09fe85/640/d02536f0-83d7-4416-9cea-f6213e09fe85.png)
![(R)-1-{(RP)-2-[2-(Diphenylphosphino)phenyl]ferrocenyl}ethylbis[3,5-bis-(trifluoromethyl)phenyl]phosphine ≥97%](/deepweb/assets/sigmaaldrich/product/structures/185/002/97358faf-b2d8-4de5-9315-73b6a8b3ae26/640/97358faf-b2d8-4de5-9315-73b6a8b3ae26.png)
![O-[2-(3-Mercaptopropionylamino)ethyl]-O′-methylpolyethylene glycol 5,000](/deepweb/assets/sigmaaldrich/product/structures/293/792/95ae9557-6907-4575-8903-f5b87ada86e2/640/95ae9557-6907-4575-8903-f5b87ada86e2.png)
form
powder
mol wt
Mw 3000
reaction suitability
reagent type: cross-linking reagent
Ω-end
thiol
α-end
carboxylic acid
storage temp.
−20°C
¿Está buscando productos similares? Visita Guía de comparación de productos
Categorías relacionadas
Packaging
Storage Class
11 - Combustible Solids
wgk_germany
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Gloves, type N95 (US)
Certificados de análisis (COA)
Busque Certificados de análisis (COA) introduciendo el número de lote del producto. Los números de lote se encuentran en la etiqueta del producto después de las palabras «Lot» o «Batch»
¿Ya tiene este producto?
Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.
Los clientes también vieron
Artículos
Circulatory half-life is a key success factor for new drugs. In this respect, PEGylation or PEG-ing—the modification of potential candidates ranging from non-peptidic small molecules to peptides and proteins, antibody fragments, aptamers, and saccharides or oligonucleotides with polyethylene glycol chains—offers numerous advantages.
Circulatory half-life is a key success factor for new drugs. In this respect, PEGylation or PEG-ing—the modification of potential candidates ranging from non-peptidic small molecules to peptides and proteins, antibody fragments, aptamers, and saccharides or oligonucleotides with polyethylene glycol chains—offers numerous advantages.
Circulatory half-life is a key success factor for new drugs. In this respect, PEGylation or PEG-ing—the modification of potential candidates ranging from non-peptidic small molecules to peptides and proteins, antibody fragments, aptamers, and saccharides or oligonucleotides with polyethylene glycol chains—offers numerous advantages.
Circulatory half-life is a key success factor for new drugs. In this respect, PEGylation or PEG-ing—the modification of potential candidates ranging from non-peptidic small molecules to peptides and proteins, antibody fragments, aptamers, and saccharides or oligonucleotides with polyethylene glycol chains—offers numerous advantages.
Protocolos
Science Slam panel: Leading gene therapy developers discuss commercialization challenges and the importance of robust process development plans.
Science Slam panel: Leading gene therapy developers discuss commercialization challenges and the importance of robust process development plans.
Science Slam panel: Leading gene therapy developers discuss commercialization challenges and the importance of robust process development plans.
Science Slam panel: Leading gene therapy developers discuss commercialization challenges and the importance of robust process development plans.
Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.
Póngase en contacto con el Servicio técnico